nodes	percent_of_prediction	percent_of_DWPC	metapath
Lenalidomide—ABCB1—Lisinopril—systemic scleroderma	0.0845	0.328	CbGbCtD
Lenalidomide—TNFSF11—skeletal joint—systemic scleroderma	0.0655	0.313	CbGeAlD
Lenalidomide—ABCB1—Captopril—systemic scleroderma	0.0633	0.246	CbGbCtD
Lenalidomide—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0498	0.194	CbGbCtD
Lenalidomide—ABCB1—Prednisone—systemic scleroderma	0.0398	0.155	CbGbCtD
Lenalidomide—CDH5—artery—systemic scleroderma	0.0206	0.0986	CbGeAlD
Lenalidomide—ABCB1—Methotrexate—systemic scleroderma	0.02	0.0776	CbGbCtD
Lenalidomide—CDH5—endothelium—systemic scleroderma	0.0174	0.0832	CbGeAlD
Lenalidomide—CDH5—blood vessel—systemic scleroderma	0.0161	0.0768	CbGeAlD
Lenalidomide—TNFSF11—connective tissue—systemic scleroderma	0.011	0.0523	CbGeAlD
Lenalidomide—PTGS2—skeletal joint—systemic scleroderma	0.00852	0.0407	CbGeAlD
Lenalidomide—CDH5—connective tissue—systemic scleroderma	0.00824	0.0394	CbGeAlD
Lenalidomide—CDH5—smooth muscle tissue—systemic scleroderma	0.00754	0.036	CbGeAlD
Lenalidomide—TNFSF11—tendon—systemic scleroderma	0.00753	0.036	CbGeAlD
Lenalidomide—TNFSF11—lung—systemic scleroderma	0.00661	0.0316	CbGeAlD
Lenalidomide—CDH5—tendon—systemic scleroderma	0.00566	0.0271	CbGeAlD
Lenalidomide—CDH5—lung—systemic scleroderma	0.00497	0.0237	CbGeAlD
Lenalidomide—CRBN—digestive system—systemic scleroderma	0.00378	0.0181	CbGeAlD
Lenalidomide—PTGS2—Fluocinonide—Mometasone—systemic scleroderma	0.00363	0.624	CbGdCrCtD
Lenalidomide—CRBN—tendon—systemic scleroderma	0.0036	0.0172	CbGeAlD
Lenalidomide—PTGS2—artery—systemic scleroderma	0.00357	0.017	CbGeAlD
Lenalidomide—CRBN—lung—systemic scleroderma	0.00316	0.0151	CbGeAlD
Lenalidomide—PTGS2—endothelium—systemic scleroderma	0.00301	0.0144	CbGeAlD
Lenalidomide—PTGS2—blood vessel—systemic scleroderma	0.00278	0.0133	CbGeAlD
Lenalidomide—PTGS2—Fluticasone Propionate—Mometasone—systemic scleroderma	0.00219	0.376	CbGdCrCtD
Lenalidomide—ABCB1—blood vessel—systemic scleroderma	0.00172	0.00821	CbGeAlD
Lenalidomide—PTGS2—connective tissue—systemic scleroderma	0.00143	0.00681	CbGeAlD
Lenalidomide—PTGS2—smooth muscle tissue—systemic scleroderma	0.0013	0.00623	CbGeAlD
Lenalidomide—PTGS2—skin of body—systemic scleroderma	0.00129	0.00615	CbGeAlD
Lenalidomide—PTGS2—digestive system—systemic scleroderma	0.00103	0.00492	CbGeAlD
Lenalidomide—PTGS2—tendon—systemic scleroderma	0.00098	0.00468	CbGeAlD
Lenalidomide—PTGS2—lung—systemic scleroderma	0.00086	0.00411	CbGeAlD
Lenalidomide—ABCB1—digestive system—systemic scleroderma	0.000637	0.00304	CbGeAlD
Lenalidomide—ABCB1—lung—systemic scleroderma	0.000532	0.00254	CbGeAlD
Lenalidomide—Breast disorder—Methotrexate—systemic scleroderma	0.000153	0.00029	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000153	0.000289	CcSEcCtD
Lenalidomide—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000153	0.000289	CcSEcCtD
Lenalidomide—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	0.000152	0.000289	CcSEcCtD
Lenalidomide—Hypersensitivity—Azathioprine—systemic scleroderma	0.000152	0.000288	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000152	0.000288	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000152	0.000288	CcSEcCtD
Lenalidomide—Insomnia—Lisinopril—systemic scleroderma	0.000151	0.000287	CcSEcCtD
Lenalidomide—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000151	0.000287	CcSEcCtD
Lenalidomide—Paraesthesia—Lisinopril—systemic scleroderma	0.00015	0.000285	CcSEcCtD
Lenalidomide—Vomiting—Captopril—systemic scleroderma	0.00015	0.000285	CcSEcCtD
Lenalidomide—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.00015	0.000284	CcSEcCtD
Lenalidomide—Dyspnoea—Lisinopril—systemic scleroderma	0.000149	0.000283	CcSEcCtD
Lenalidomide—Rash—Captopril—systemic scleroderma	0.000149	0.000283	CcSEcCtD
Lenalidomide—Dermatitis—Captopril—systemic scleroderma	0.000149	0.000282	CcSEcCtD
Lenalidomide—Somnolence—Lisinopril—systemic scleroderma	0.000149	0.000282	CcSEcCtD
Lenalidomide—Headache—Captopril—systemic scleroderma	0.000148	0.000281	CcSEcCtD
Lenalidomide—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000148	0.000281	CcSEcCtD
Lenalidomide—Dyspepsia—Lisinopril—systemic scleroderma	0.000147	0.00028	CcSEcCtD
Lenalidomide—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000147	0.000279	CcSEcCtD
Lenalidomide—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000147	0.000279	CcSEcCtD
Lenalidomide—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000147	0.000278	CcSEcCtD
Lenalidomide—Asthma—Methotrexate—systemic scleroderma	0.000146	0.000277	CcSEcCtD
Lenalidomide—Infection—Mycophenolate mofetil—systemic scleroderma	0.000146	0.000276	CcSEcCtD
Lenalidomide—Decreased appetite—Lisinopril—systemic scleroderma	0.000146	0.000276	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000145	0.000274	CcSEcCtD
Lenalidomide—Fatigue—Lisinopril—systemic scleroderma	0.000144	0.000274	CcSEcCtD
Lenalidomide—Shock—Mycophenolate mofetil—systemic scleroderma	0.000144	0.000274	CcSEcCtD
Lenalidomide—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000144	0.000273	CcSEcCtD
Lenalidomide—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000144	0.000272	CcSEcCtD
Lenalidomide—Hypersensitivity—Leflunomide—systemic scleroderma	0.000144	0.000272	CcSEcCtD
Lenalidomide—Pancreatitis—Methotrexate—systemic scleroderma	0.000143	0.000272	CcSEcCtD
Lenalidomide—Pain—Lisinopril—systemic scleroderma	0.000143	0.000272	CcSEcCtD
Lenalidomide—Constipation—Lisinopril—systemic scleroderma	0.000143	0.000272	CcSEcCtD
Lenalidomide—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000143	0.000272	CcSEcCtD
Lenalidomide—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000143	0.00027	CcSEcCtD
Lenalidomide—Bradycardia—Prednisone—systemic scleroderma	0.000143	0.00027	CcSEcCtD
Lenalidomide—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000142	0.000269	CcSEcCtD
Lenalidomide—Diarrhoea—Azathioprine—systemic scleroderma	0.000141	0.000268	CcSEcCtD
Lenalidomide—Haemoglobin—Prednisone—systemic scleroderma	0.000141	0.000267	CcSEcCtD
Lenalidomide—Nausea—Captopril—systemic scleroderma	0.00014	0.000266	CcSEcCtD
Lenalidomide—Abdominal discomfort—Methotrexate—systemic scleroderma	0.00014	0.000266	CcSEcCtD
Lenalidomide—Haemorrhage—Prednisone—systemic scleroderma	0.00014	0.000265	CcSEcCtD
Lenalidomide—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.00014	0.000265	CcSEcCtD
Lenalidomide—Asthenia—Leflunomide—systemic scleroderma	0.00014	0.000265	CcSEcCtD
Lenalidomide—Hallucination—Prednisone—systemic scleroderma	0.000139	0.000264	CcSEcCtD
Lenalidomide—Pancytopenia—Methotrexate—systemic scleroderma	0.000139	0.000263	CcSEcCtD
Lenalidomide—Feeling abnormal—Lisinopril—systemic scleroderma	0.000138	0.000262	CcSEcCtD
Lenalidomide—Pruritus—Leflunomide—systemic scleroderma	0.000138	0.000261	CcSEcCtD
Lenalidomide—Connective tissue disorder—Prednisone—systemic scleroderma	0.000138	0.000261	CcSEcCtD
Lenalidomide—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000137	0.00026	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000137	0.00026	CcSEcCtD
Lenalidomide—Neutropenia—Methotrexate—systemic scleroderma	0.000137	0.000259	CcSEcCtD
Lenalidomide—Dysuria—Methotrexate—systemic scleroderma	0.000137	0.000259	CcSEcCtD
Lenalidomide—Dizziness—Azathioprine—systemic scleroderma	0.000136	0.000259	CcSEcCtD
Lenalidomide—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.000136	0.000258	CcSEcCtD
Lenalidomide—Erectile dysfunction—Methotrexate—systemic scleroderma	0.000135	0.000255	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000134	0.000253	CcSEcCtD
Lenalidomide—Photosensitivity reaction—Methotrexate—systemic scleroderma	0.000133	0.000253	CcSEcCtD
Lenalidomide—Asthenia—Mycophenolic acid—systemic scleroderma	0.000133	0.000253	CcSEcCtD
Lenalidomide—Diarrhoea—Leflunomide—systemic scleroderma	0.000133	0.000253	CcSEcCtD
Lenalidomide—Urticaria—Lisinopril—systemic scleroderma	0.000133	0.000252	CcSEcCtD
Lenalidomide—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000133	0.000252	CcSEcCtD
Lenalidomide—Abdominal pain—Lisinopril—systemic scleroderma	0.000132	0.000251	CcSEcCtD
Lenalidomide—Body temperature increased—Lisinopril—systemic scleroderma	0.000132	0.000251	CcSEcCtD
Lenalidomide—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000132	0.00025	CcSEcCtD
Lenalidomide—Pruritus—Mycophenolic acid—systemic scleroderma	0.000132	0.000249	CcSEcCtD
Lenalidomide—Vomiting—Azathioprine—systemic scleroderma	0.000131	0.000249	CcSEcCtD
Lenalidomide—Pneumonia—Methotrexate—systemic scleroderma	0.000131	0.000249	CcSEcCtD
Lenalidomide—Eye disorder—Prednisone—systemic scleroderma	0.000131	0.000248	CcSEcCtD
Lenalidomide—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000131	0.000248	CcSEcCtD
Lenalidomide—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.00013	0.000247	CcSEcCtD
Lenalidomide—Infestation—Methotrexate—systemic scleroderma	0.00013	0.000247	CcSEcCtD
Lenalidomide—Infestation NOS—Methotrexate—systemic scleroderma	0.00013	0.000247	CcSEcCtD
Lenalidomide—Rash—Azathioprine—systemic scleroderma	0.00013	0.000247	CcSEcCtD
Lenalidomide—Dermatitis—Azathioprine—systemic scleroderma	0.00013	0.000246	CcSEcCtD
Lenalidomide—Depression—Methotrexate—systemic scleroderma	0.00013	0.000246	CcSEcCtD
Lenalidomide—Flushing—Prednisone—systemic scleroderma	0.00013	0.000246	CcSEcCtD
Lenalidomide—Headache—Azathioprine—systemic scleroderma	0.000129	0.000245	CcSEcCtD
Lenalidomide—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.000129	0.000245	CcSEcCtD
Lenalidomide—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000129	0.000245	CcSEcCtD
Lenalidomide—Dizziness—Leflunomide—systemic scleroderma	0.000129	0.000244	CcSEcCtD
Lenalidomide—Renal failure—Methotrexate—systemic scleroderma	0.000128	0.000243	CcSEcCtD
Lenalidomide—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000128	0.000242	CcSEcCtD
Lenalidomide—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000127	0.000241	CcSEcCtD
Lenalidomide—Stomatitis—Methotrexate—systemic scleroderma	0.000127	0.000241	CcSEcCtD
Lenalidomide—Angiopathy—Prednisone—systemic scleroderma	0.000127	0.000241	CcSEcCtD
Lenalidomide—Conjunctivitis—Methotrexate—systemic scleroderma	0.000127	0.00024	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000127	0.00024	CcSEcCtD
Lenalidomide—Immune system disorder—Prednisone—systemic scleroderma	0.000126	0.00024	CcSEcCtD
Lenalidomide—Pain—Mycophenolate mofetil—systemic scleroderma	0.000125	0.000238	CcSEcCtD
Lenalidomide—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000125	0.000238	CcSEcCtD
Lenalidomide—Arrhythmia—Prednisone—systemic scleroderma	0.000125	0.000237	CcSEcCtD
Lenalidomide—Sweating—Methotrexate—systemic scleroderma	0.000125	0.000237	CcSEcCtD
Lenalidomide—Haematuria—Methotrexate—systemic scleroderma	0.000124	0.000236	CcSEcCtD
Lenalidomide—Vomiting—Leflunomide—systemic scleroderma	0.000124	0.000235	CcSEcCtD
Lenalidomide—Alopecia—Prednisone—systemic scleroderma	0.000124	0.000235	CcSEcCtD
Lenalidomide—Hypersensitivity—Lisinopril—systemic scleroderma	0.000123	0.000234	CcSEcCtD
Lenalidomide—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000123	0.000234	CcSEcCtD
Lenalidomide—Dizziness—Mycophenolic acid—systemic scleroderma	0.000123	0.000233	CcSEcCtD
Lenalidomide—Epistaxis—Methotrexate—systemic scleroderma	0.000123	0.000233	CcSEcCtD
Lenalidomide—Rash—Leflunomide—systemic scleroderma	0.000123	0.000233	CcSEcCtD
Lenalidomide—Dermatitis—Leflunomide—systemic scleroderma	0.000123	0.000233	CcSEcCtD
Lenalidomide—Mental disorder—Prednisone—systemic scleroderma	0.000123	0.000233	CcSEcCtD
Lenalidomide—Nausea—Azathioprine—systemic scleroderma	0.000123	0.000232	CcSEcCtD
Lenalidomide—Headache—Leflunomide—systemic scleroderma	0.000122	0.000232	CcSEcCtD
Lenalidomide—Malnutrition—Prednisone—systemic scleroderma	0.000122	0.000231	CcSEcCtD
Lenalidomide—Erythema—Prednisone—systemic scleroderma	0.000122	0.000231	CcSEcCtD
Lenalidomide—Agranulocytosis—Methotrexate—systemic scleroderma	0.000122	0.000231	CcSEcCtD
Lenalidomide—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000121	0.000229	CcSEcCtD
Lenalidomide—Asthenia—Lisinopril—systemic scleroderma	0.00012	0.000228	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.00012	0.000227	CcSEcCtD
Lenalidomide—Pruritus—Lisinopril—systemic scleroderma	0.000118	0.000225	CcSEcCtD
Lenalidomide—Vomiting—Mycophenolic acid—systemic scleroderma	0.000118	0.000224	CcSEcCtD
Lenalidomide—Haemoglobin—Methotrexate—systemic scleroderma	0.000118	0.000223	CcSEcCtD
Lenalidomide—Rash—Mycophenolic acid—systemic scleroderma	0.000117	0.000222	CcSEcCtD
Lenalidomide—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000117	0.000222	CcSEcCtD
Lenalidomide—Haemorrhage—Methotrexate—systemic scleroderma	0.000117	0.000222	CcSEcCtD
Lenalidomide—Hepatitis—Methotrexate—systemic scleroderma	0.000117	0.000222	CcSEcCtD
Lenalidomide—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000117	0.000221	CcSEcCtD
Lenalidomide—Headache—Mycophenolic acid—systemic scleroderma	0.000116	0.000221	CcSEcCtD
Lenalidomide—Pharyngitis—Methotrexate—systemic scleroderma	0.000116	0.00022	CcSEcCtD
Lenalidomide—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000116	0.00022	CcSEcCtD
Lenalidomide—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000116	0.00022	CcSEcCtD
Lenalidomide—Nausea—Leflunomide—systemic scleroderma	0.000116	0.000219	CcSEcCtD
Lenalidomide—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000116	0.000219	CcSEcCtD
Lenalidomide—Vision blurred—Prednisone—systemic scleroderma	0.000115	0.000218	CcSEcCtD
Lenalidomide—Urethral disorder—Methotrexate—systemic scleroderma	0.000115	0.000217	CcSEcCtD
Lenalidomide—Diarrhoea—Lisinopril—systemic scleroderma	0.000115	0.000217	CcSEcCtD
Lenalidomide—Ill-defined disorder—Prednisone—systemic scleroderma	0.000113	0.000214	CcSEcCtD
Lenalidomide—Visual impairment—Methotrexate—systemic scleroderma	0.000113	0.000214	CcSEcCtD
Lenalidomide—Anaemia—Prednisone—systemic scleroderma	0.000113	0.000214	CcSEcCtD
Lenalidomide—Agitation—Prednisone—systemic scleroderma	0.000112	0.000212	CcSEcCtD
Lenalidomide—Angioedema—Prednisone—systemic scleroderma	0.000111	0.000211	CcSEcCtD
Lenalidomide—Dizziness—Lisinopril—systemic scleroderma	0.000111	0.00021	CcSEcCtD
Lenalidomide—Erythema multiforme—Methotrexate—systemic scleroderma	0.000111	0.00021	CcSEcCtD
Lenalidomide—Nausea—Mycophenolic acid—systemic scleroderma	0.00011	0.000209	CcSEcCtD
Lenalidomide—Malaise—Prednisone—systemic scleroderma	0.00011	0.000208	CcSEcCtD
Lenalidomide—Vertigo—Prednisone—systemic scleroderma	0.00011	0.000208	CcSEcCtD
Lenalidomide—Eye disorder—Methotrexate—systemic scleroderma	0.000109	0.000207	CcSEcCtD
Lenalidomide—Syncope—Prednisone—systemic scleroderma	0.000109	0.000207	CcSEcCtD
Lenalidomide—Tinnitus—Methotrexate—systemic scleroderma	0.000109	0.000207	CcSEcCtD
Lenalidomide—Cardiac disorder—Methotrexate—systemic scleroderma	0.000109	0.000206	CcSEcCtD
Lenalidomide—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000108	0.000205	CcSEcCtD
Lenalidomide—Loss of consciousness—Prednisone—systemic scleroderma	0.000107	0.000203	CcSEcCtD
Lenalidomide—Vomiting—Lisinopril—systemic scleroderma	0.000106	0.000202	CcSEcCtD
Lenalidomide—Angiopathy—Methotrexate—systemic scleroderma	0.000106	0.000201	CcSEcCtD
Lenalidomide—Immune system disorder—Methotrexate—systemic scleroderma	0.000106	0.0002	CcSEcCtD
Lenalidomide—Rash—Lisinopril—systemic scleroderma	0.000106	0.0002	CcSEcCtD
Lenalidomide—Dermatitis—Lisinopril—systemic scleroderma	0.000106	0.0002	CcSEcCtD
Lenalidomide—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000105	0.0002	CcSEcCtD
Lenalidomide—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000105	0.0002	CcSEcCtD
Lenalidomide—Hypertension—Prednisone—systemic scleroderma	0.000105	0.000199	CcSEcCtD
Lenalidomide—Chills—Methotrexate—systemic scleroderma	0.000105	0.000199	CcSEcCtD
Lenalidomide—Headache—Lisinopril—systemic scleroderma	0.000105	0.000199	CcSEcCtD
Lenalidomide—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000104	0.000197	CcSEcCtD
Lenalidomide—Arthralgia—Prednisone—systemic scleroderma	0.000104	0.000197	CcSEcCtD
Lenalidomide—Myalgia—Prednisone—systemic scleroderma	0.000104	0.000197	CcSEcCtD
Lenalidomide—Anxiety—Prednisone—systemic scleroderma	0.000103	0.000196	CcSEcCtD
Lenalidomide—Alopecia—Methotrexate—systemic scleroderma	0.000103	0.000196	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000103	0.000195	CcSEcCtD
Lenalidomide—Discomfort—Prednisone—systemic scleroderma	0.000103	0.000194	CcSEcCtD
Lenalidomide—Mental disorder—Methotrexate—systemic scleroderma	0.000103	0.000194	CcSEcCtD
Lenalidomide—Erythema—Methotrexate—systemic scleroderma	0.000102	0.000193	CcSEcCtD
Lenalidomide—Malnutrition—Methotrexate—systemic scleroderma	0.000102	0.000193	CcSEcCtD
Lenalidomide—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.0001	0.00019	CcSEcCtD
Lenalidomide—Dysgeusia—Methotrexate—systemic scleroderma	9.97e-05	0.000189	CcSEcCtD
Lenalidomide—Nausea—Lisinopril—systemic scleroderma	9.95e-05	0.000189	CcSEcCtD
Lenalidomide—Oedema—Prednisone—systemic scleroderma	9.95e-05	0.000189	CcSEcCtD
Lenalidomide—Infection—Prednisone—systemic scleroderma	9.88e-05	0.000187	CcSEcCtD
Lenalidomide—Back pain—Methotrexate—systemic scleroderma	9.85e-05	0.000187	CcSEcCtD
Lenalidomide—Shock—Prednisone—systemic scleroderma	9.79e-05	0.000186	CcSEcCtD
Lenalidomide—Nervous system disorder—Prednisone—systemic scleroderma	9.75e-05	0.000185	CcSEcCtD
Lenalidomide—Tachycardia—Prednisone—systemic scleroderma	9.71e-05	0.000184	CcSEcCtD
Lenalidomide—Dizziness—Mycophenolate mofetil—systemic scleroderma	9.7e-05	0.000184	CcSEcCtD
Lenalidomide—Skin disorder—Prednisone—systemic scleroderma	9.66e-05	0.000183	CcSEcCtD
Lenalidomide—Hyperhidrosis—Prednisone—systemic scleroderma	9.62e-05	0.000182	CcSEcCtD
Lenalidomide—Vision blurred—Methotrexate—systemic scleroderma	9.6e-05	0.000182	CcSEcCtD
Lenalidomide—Anorexia—Prednisone—systemic scleroderma	9.48e-05	0.00018	CcSEcCtD
Lenalidomide—Ill-defined disorder—Methotrexate—systemic scleroderma	9.45e-05	0.000179	CcSEcCtD
Lenalidomide—Anaemia—Methotrexate—systemic scleroderma	9.41e-05	0.000178	CcSEcCtD
Lenalidomide—Vomiting—Mycophenolate mofetil—systemic scleroderma	9.33e-05	0.000177	CcSEcCtD
Lenalidomide—Rash—Mycophenolate mofetil—systemic scleroderma	9.25e-05	0.000175	CcSEcCtD
Lenalidomide—Dermatitis—Mycophenolate mofetil—systemic scleroderma	9.24e-05	0.000175	CcSEcCtD
Lenalidomide—Headache—Mycophenolate mofetil—systemic scleroderma	9.19e-05	0.000174	CcSEcCtD
Lenalidomide—Malaise—Methotrexate—systemic scleroderma	9.19e-05	0.000174	CcSEcCtD
Lenalidomide—Vertigo—Methotrexate—systemic scleroderma	9.15e-05	0.000173	CcSEcCtD
Lenalidomide—Leukopenia—Methotrexate—systemic scleroderma	9.12e-05	0.000173	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Prednisone—systemic scleroderma	9.06e-05	0.000172	CcSEcCtD
Lenalidomide—Insomnia—Prednisone—systemic scleroderma	9e-05	0.000171	CcSEcCtD
Lenalidomide—Paraesthesia—Prednisone—systemic scleroderma	8.93e-05	0.000169	CcSEcCtD
Lenalidomide—Cough—Methotrexate—systemic scleroderma	8.89e-05	0.000169	CcSEcCtD
Lenalidomide—Dyspepsia—Prednisone—systemic scleroderma	8.76e-05	0.000166	CcSEcCtD
Lenalidomide—Nausea—Mycophenolate mofetil—systemic scleroderma	8.72e-05	0.000165	CcSEcCtD
Lenalidomide—Myalgia—Methotrexate—systemic scleroderma	8.67e-05	0.000164	CcSEcCtD
Lenalidomide—Chest pain—Methotrexate—systemic scleroderma	8.67e-05	0.000164	CcSEcCtD
Lenalidomide—Arthralgia—Methotrexate—systemic scleroderma	8.67e-05	0.000164	CcSEcCtD
Lenalidomide—Decreased appetite—Prednisone—systemic scleroderma	8.65e-05	0.000164	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	8.61e-05	0.000163	CcSEcCtD
Lenalidomide—Fatigue—Prednisone—systemic scleroderma	8.58e-05	0.000163	CcSEcCtD
Lenalidomide—Discomfort—Methotrexate—systemic scleroderma	8.57e-05	0.000162	CcSEcCtD
Lenalidomide—Constipation—Prednisone—systemic scleroderma	8.51e-05	0.000161	CcSEcCtD
Lenalidomide—Confusional state—Methotrexate—systemic scleroderma	8.38e-05	0.000159	CcSEcCtD
Lenalidomide—Infection—Methotrexate—systemic scleroderma	8.26e-05	0.000157	CcSEcCtD
Lenalidomide—Feeling abnormal—Prednisone—systemic scleroderma	8.2e-05	0.000155	CcSEcCtD
Lenalidomide—Nervous system disorder—Methotrexate—systemic scleroderma	8.15e-05	0.000155	CcSEcCtD
Lenalidomide—Thrombocytopenia—Methotrexate—systemic scleroderma	8.14e-05	0.000154	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Prednisone—systemic scleroderma	8.13e-05	0.000154	CcSEcCtD
Lenalidomide—Skin disorder—Methotrexate—systemic scleroderma	8.07e-05	0.000153	CcSEcCtD
Lenalidomide—Hyperhidrosis—Methotrexate—systemic scleroderma	8.04e-05	0.000152	CcSEcCtD
Lenalidomide—Anorexia—Methotrexate—systemic scleroderma	7.92e-05	0.00015	CcSEcCtD
Lenalidomide—Urticaria—Prednisone—systemic scleroderma	7.9e-05	0.00015	CcSEcCtD
Lenalidomide—Abdominal pain—Prednisone—systemic scleroderma	7.86e-05	0.000149	CcSEcCtD
Lenalidomide—Body temperature increased—Prednisone—systemic scleroderma	7.86e-05	0.000149	CcSEcCtD
Lenalidomide—Hypotension—Methotrexate—systemic scleroderma	7.77e-05	0.000147	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	7.57e-05	0.000144	CcSEcCtD
Lenalidomide—Insomnia—Methotrexate—systemic scleroderma	7.52e-05	0.000143	CcSEcCtD
Lenalidomide—Paraesthesia—Methotrexate—systemic scleroderma	7.46e-05	0.000142	CcSEcCtD
Lenalidomide—Dyspnoea—Methotrexate—systemic scleroderma	7.41e-05	0.000141	CcSEcCtD
Lenalidomide—Somnolence—Methotrexate—systemic scleroderma	7.39e-05	0.00014	CcSEcCtD
Lenalidomide—Hypersensitivity—Prednisone—systemic scleroderma	7.33e-05	0.000139	CcSEcCtD
Lenalidomide—Dyspepsia—Methotrexate—systemic scleroderma	7.32e-05	0.000139	CcSEcCtD
Lenalidomide—Decreased appetite—Methotrexate—systemic scleroderma	7.23e-05	0.000137	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Methotrexate—systemic scleroderma	7.18e-05	0.000136	CcSEcCtD
Lenalidomide—Fatigue—Methotrexate—systemic scleroderma	7.17e-05	0.000136	CcSEcCtD
Lenalidomide—Asthenia—Prednisone—systemic scleroderma	7.14e-05	0.000135	CcSEcCtD
Lenalidomide—Pain—Methotrexate—systemic scleroderma	7.11e-05	0.000135	CcSEcCtD
Lenalidomide—Pruritus—Prednisone—systemic scleroderma	7.04e-05	0.000133	CcSEcCtD
Lenalidomide—Feeling abnormal—Methotrexate—systemic scleroderma	6.85e-05	0.00013	CcSEcCtD
Lenalidomide—Diarrhoea—Prednisone—systemic scleroderma	6.81e-05	0.000129	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Methotrexate—systemic scleroderma	6.8e-05	0.000129	CcSEcCtD
Lenalidomide—Urticaria—Methotrexate—systemic scleroderma	6.6e-05	0.000125	CcSEcCtD
Lenalidomide—Dizziness—Prednisone—systemic scleroderma	6.58e-05	0.000125	CcSEcCtD
Lenalidomide—Abdominal pain—Methotrexate—systemic scleroderma	6.57e-05	0.000125	CcSEcCtD
Lenalidomide—Body temperature increased—Methotrexate—systemic scleroderma	6.57e-05	0.000125	CcSEcCtD
Lenalidomide—Vomiting—Prednisone—systemic scleroderma	6.32e-05	0.00012	CcSEcCtD
Lenalidomide—Rash—Prednisone—systemic scleroderma	6.27e-05	0.000119	CcSEcCtD
Lenalidomide—Dermatitis—Prednisone—systemic scleroderma	6.27e-05	0.000119	CcSEcCtD
Lenalidomide—Headache—Prednisone—systemic scleroderma	6.23e-05	0.000118	CcSEcCtD
Lenalidomide—Hypersensitivity—Methotrexate—systemic scleroderma	6.12e-05	0.000116	CcSEcCtD
Lenalidomide—Asthenia—Methotrexate—systemic scleroderma	5.96e-05	0.000113	CcSEcCtD
Lenalidomide—Nausea—Prednisone—systemic scleroderma	5.91e-05	0.000112	CcSEcCtD
Lenalidomide—Pruritus—Methotrexate—systemic scleroderma	5.88e-05	0.000112	CcSEcCtD
Lenalidomide—Diarrhoea—Methotrexate—systemic scleroderma	5.69e-05	0.000108	CcSEcCtD
Lenalidomide—Dizziness—Methotrexate—systemic scleroderma	5.5e-05	0.000104	CcSEcCtD
Lenalidomide—Vomiting—Methotrexate—systemic scleroderma	5.29e-05	0.0001	CcSEcCtD
Lenalidomide—Rash—Methotrexate—systemic scleroderma	5.24e-05	9.94e-05	CcSEcCtD
Lenalidomide—Dermatitis—Methotrexate—systemic scleroderma	5.24e-05	9.93e-05	CcSEcCtD
Lenalidomide—Headache—Methotrexate—systemic scleroderma	5.21e-05	9.87e-05	CcSEcCtD
Lenalidomide—Nausea—Methotrexate—systemic scleroderma	4.94e-05	9.36e-05	CcSEcCtD
